Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osimertinib alone is the usual treatment for metastatic EGFR-mutant lung cancer. Researchers think adding chemotherapy to osimertinib could possibly add to the anticancer effects of the usual treatment and help stop cancer from growing or spreading.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony w biopsji przerzutowy rak płuc (niepłaskonabłonkowy)
- •Mutacja genu EGFR potwierdzona w próbce guza lub płynie opłucnowym
- •Możliwość głoszenia leków w tabletkach
- •Wystarczająco dobre funkcjonowanie nerek (przesączanie ≥60 ml/min)
- •Wystarczająco dobre funkcjonowanie wątroby i poziom hemoglobiny
- •Stan ogólny pacjenta pozwalający na pracę bez większych ograniczeń
- •Zgodność na stosowanie skutecznych metod antykoncepcji (dla osób w wieku rozrodczym)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 12, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (18)
UC Davis Cancer Center (Data Collection Only)
Sacramento, United States
University of California San Francisco
San Francisco, United States
Moffitt Cancer Center
Tampa, United States
John Hopkins Medical Center
Baltimore, United States
Massachusetts General Hospital (Data Collection Only)
Boston, United States
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, United States
Hackensack Meridian Health
Hackensack, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, United States
Memorial Sloan Kettering Commack (Limited protocol activities)
Commack, United States
Memorial Sloan Kettering Westchester (Limited protocol activities)
Harrison, United States
New York University
New York, United States
Columbia University (Data Collection Only)
New York, United States
Memorial Sloan Kettering Cancer Center (All protocol activities)
New York, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, United States
Sarah Cannon Research Institute
Nashville, United States
MD ANDERSON CANCER CENTER (Data Collection Only)
Houston, United States
University of Washington (Data Collection Only)
Seattle, United States
Trial contact
Helena Yu, MD
Gregory Riely, MD, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.